Cedric Szyndralewiez
Geneve, GE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Pre-clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis.
Journal: Journal of cellular and molecular medicine
Published: September 12, 2022
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.
Journal: Cancer research
Published: October 10, 2019
Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy.
Journal: Life science alliance
Published: December 06, 2018
Nox4 is a Target for Tuberin Deficiency Syndrome.
Journal: Scientific reports
Published: October 18, 2017
Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.
Journal: International journal of cancer
Published: August 22, 2017
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.
Journal: Journal of the National Cancer Institute
Published: October 03, 2016
Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.
Journal: Diabetologia
Published: September 29, 2016
Airway smooth muscle NOX4 is upregulated and modulates ROS generation in COPD.
Journal: Respiratory research
Published: May 14, 2016
NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis.
Journal: Free radical biology & medicine
Published: May 07, 2016
Therapeutic potential of NADPH oxidase 1/4 inhibitors.
Journal: British journal of pharmacology
Published: September 30, 2015
Last Updated: 09/26/2026